Auxilium Pharmaceuticals (AUXL)

Add to Watchlists Create an Alert
15.18 -0.08  -0.52%   NASDAQ May 24, 8:00PM BATS Real time Currency in USD

Auxilium Pharmaceuticals R&D Expense Quarterly:

11.86M for March 31, 2013
View Full Chart

Auxilium Pharmaceuticals R&D Expense Quarterly Chart

    Auxilium Pharmaceuticals Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 11.86M
    Dec. 31, 2012 13.16M
    Sept. 30, 2012 10.59M
    June 30, 2012 10.19M
    March 31, 2012 11.99M
    Dec. 31, 2011 18.72M
    Sept. 30, 2011 14.16M
    June 30, 2011 13.32M
    March 31, 2011 15.75M
    Dec. 31, 2010 13.96M
    Sept. 30, 2010 14.43M
    June 30, 2010 11.14M
    March 31, 2010 8.479M
    Dec. 31, 2009 11.38M
    Sept. 30, 2009 12.75M
    June 30, 2009 13.73M
    March 31, 2009 13.53M
    Dec. 31, 2008 14.59M
    Sept. 30, 2008 13.28M
    June 30, 2008 13.44M
       
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    AUXL R&D Expense Quarterly Benchmarks

    Companies
    Endo Health Solutions 41.57M
    BioSpecifics Technologies Corporation 0.2949M
    Pfizer 1.80B

    AUXL R&D Expense Quarterly Rankings

    Overall 93rd percentile
    536 of 8011
    Sector 79th percentile
    139 of 687 in Healthcare
    Industry 69th percentile
    21 of 69 in Drug Manufacturers - Specialty & Generic

    AUXL R&D Expense Quarterly Range, Past 5 Years

    Minimum 8.479M Mar 2010
    Maximum 18.72M Dec 2011
    Average 13.02M